About the Event
In this installment of Psychiatry and Behavioral Grand Rounds, Paul E. Holtzheimer, M.D., presents “Transcranial Magnetic Stimulation for Psychiatric Disorders.” Holtzheimer is a professor of psychiatry and surgery and the Geisel School of Medicine at Dartmouth.
For more information about the event, email Barbara Springer.
By the end of this presentation, the audience participant should be able to:
- Describe what transcranial magnetic stimulation (TMS) is and how it may potentially work.
- Recognize the data supporting TMS as a treatment for depression.
- Assess the potential for TMS as a treatment for other psychiatric conditions, such as posttraumatic stress disorder, obsessive-compulsive disorder and addiction.
- Primary: Psychiatrists, social workers, psychologists, nurses and other mental health professionals
- Secondary: Other health care professionals
This activity has been designed to promote some of the following desired physician attributes and competencies:
- ACGME: Patient Care; Medical Knowledge; Practice-Based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; Systems-Based Practice
- IOM: Provide patient-centered care; Work in interdisciplinary teams; Employ evidence-based practice; Apply quality improvement; Utilize informatics
- IECC: Interprofessional Teamwork & Team-based Practice; Interprofessional Communication; Values & Ethics for Interprofessional Practice
Paul E Holtzheimer, MD, speaker for this educational activity, has received royalties from UpToDate and Oxford University Press.
Mark Townsend, M.D.; R. Lowell McRoberts, M.D.; Jorge Almeida, M.D., Ph.D.; Carol Alter, M.D.; Lloyd S. Berg, Ph.D.; and Barbara Springer, planners for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
Jeffrey Newport, M.D., M.S., MDiv, planner for this educational activity, received grants/research funds from Navitor Pharmaceuticals and Sage Therapeutics. He is a consultant for Sage Therapeutics.
Charles B. Nemeroff, M.D., Ph.D., planner for this educational activity, is a consultant for ANeuroTech (division of Anima BV), Taisho Pharmaceutical, Inc.,Takeda, Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage Therapeutics, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, and Corcept Therapeutics Pharmaceuticals Company.
He is a stock shareholder (directly purchased) of Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness.
Nemeroff is on the Scientific Advisory Boards for ANeuroTech (division of Anima BV), Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, and on the Board of Directors of Xhale Smart, Inc.
He holds patents for the following: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2)
The CME Advisory Committee, reviewers of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
The University of Texas at Austin Dell Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas at Austin Dell Medical School designates this internet live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.